Inhibition of CK2α and PI3K/Akt synergistically induces apoptosis of CD34+CD38- leukaemia cells while sparing haematopoietic stem cells

Anticancer Research

Volumn 30, Issue 11, 2010, Pages 4625-4634

  Cheong, June Won ^a   Min, Yoo Hong ^a   Eom, Jun In ^a   Kim, Soo Jeong ^a   Jeung, Hoi Kyung ^a   Kim, Jin Seok ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Apoptosis; CK2; Leukaemia stem cells; PI3K Akt; Synergism; Targeted therapy

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; APIGENIN; CASEIN KINASE II; CASPASE; CASPASE INHIBITOR; CD34 ANTIGEN; CD38 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL XL; PROTEIN KINASE B;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME INHIBITION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, CD34; ANTIGENS, CD38; APIGENIN; APOPTOSIS; BLOTTING, WESTERN; CASEIN KINASE II; CELLS, CULTURED; CHROMONES; CYTOSOL; DRUG SYNERGISM; ELAFIN; ENZYME INHIBITORS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MORPHOLINES; NEOPLASTIC STEM CELLS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 78650230590     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737, 1997.
2. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA and Dick JE: A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645-648, 1994.
3. Jordan CT and Guzman ML: Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene 23: 7178-7187, 2004.
4. Sutherland HJ, Blair A and Zapf RW: Characterization of a hierarchy in human acute myeloid leukemia progenitor cells. Blood 87: 4754-4761, 1996.
5. Fialkow PJ, Jacobson RJ and Papayannopoulou T: Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 63: 125-130, 1977.
6. Sincock PM and Ashman LK: Expression of c-Kit and functional drug efflux are correlated in de novo acute myeloid leukaemia. Leukemia 11: 1850-1857, 1997.
7. - cells in acute myeloid leukemia. Clin Cancer Res 11: 2436-2444, 2005.
8. Guan Y, Gerhard B and Hogge DE: Detection, isolation, and Stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 101: 3142-3149, 2003.
9. Seipelt G, Hofmann WK, Martin H, Wassmann B, Boehme A, Ottmann OG and Hoelzer D: Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin. Ann Hematol 76: 145-151, 1998.
10. Min YH, Eom JI, Cheong JW, Maeng HO, Kim JY, Jeung HK, Lee ST, Lee MH, Hahn JS and Ko YW: Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 17: 995-997, 2003.
11. Xu Q, Simpson SE, Scialla TJ, Bagg A and Carroll M: Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102: 972-980, 2003.
12. Ahmed K, Davis AT, Wang H, Faust RA, Yu S and Tawfic S: Significance of protein kinase CK2 nuclear signaling in neoplasia. J Cell Biochem Suppl 35: 130-135, 2000.
13. Landesman-Bollag E, Romieu-Mourez R, Song DH, Sonenshein GE, Cardiff RD and Selden DC: Protein kinase CK2 in mammary gland tumorigenesis. Oncogene 20: 3247-3257, 2001.
14. Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St Croix B, Romans KE, Choti MA, Lengauer C, Kinzler KW and Vogelstein B: A phosphatase associated with metastasis of colorectal cancer. Science 294: 1343-1346, 2001.
15. Kim JS, Eom JI, Cheong JW, Choi AJ, Lee JK, Yang WI and Min YH: Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia. Clin Cancer Res 13: 1019-1028, 2007.
16. Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, Brustolon F, Pinna LA and Ruzzene M: Protein kinase CK2 phosphorylates and up-regulates Akt/PKB. Cell Death Diff 12: 668-677, 2005.
17. Olsen BB, Bjorling-Poulsen M and Guerra B: Emodin negatively regulates affects the phosphoinositide 3-kinase/AKT signaling pathway: A study on its mechanism of action. Int J Biochem Biol 39: 227-237, 2007.
18. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P, Bonati A and Martelli AM: Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 22: 708-722, 2008.
19. Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P, Bonati A, Martelli AM and McCubrey JA: Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 22: 686-707, 2008.
20. Morgan MA, Dolp O and Reuter CW: Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Blood 97: 1823-1834, 2001.
21. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE and McCubrey JA: JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18: 189-218, 2004.
22. Kim SC, Hahn JS, Min YH, Yoo NC, Ko YW and Lee WJ: Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: combined role of activation of MEK, hyperexpression of extracellular signal-regulated kinase, and downregulation of a phosphatase, PAC1. Blood 93: 3893-3899, 1999.
23. Hanauske AR, Sundell K and Lahn M: The role of protein kinase C-alpha (PKC-alpha) in cancer and its modulation by the novel PKC-alpha-specific inhibitor aprinocarsen. Curr Pharm Des 10: 1923-1936, 2004.
24. Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M, Estey EH and Andreeff M: Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 108: 2358-2365, 2006.
25. Wang G, Ahmad KA and Ahmed K: Modulation of receptor mediated apoptosis by CK2. Mol Cell Biochem 274: 201-205, 2005.
26. Ruzzene M, Penzo D and Pinna LA: Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem J 364: 41-47, 2002.
27. Slaton JW, Unger GM, Sloper DT, Davis AT and Ahmed K: Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model. Mol Cancer Res 2: 712-721, 2004.
28. Wang G, Ahmad KA and Ahmed K: Role of protein kinase CK2 in regulation of TRAIL-induced apoptosis in prostate cancer cells. Cancer Res 66: 2242-2249, 2006.
29. Kelliher MA, Seldin DC and Leder P: Tal-1 induces T-cell acute lymphoblastic leukemia accelerated by casein kinase IIalpha. EMBO J 15: 5160-5166, 1996.
30. Ahmad KA, Harris NH, Johnson AD, Lindvall HC, Wang G and Ahmed K: Protein kinase CK2 modulates apoptosis induced by resveratrol and epigallocatechin-3- gallate in prostate cancer cells. Mol Cancer Ther 6: 1006-1012, 2007.
31. Shankar S, Chen Q and Srivastava RK: Inhibition of PI3K/AKT and MEK/ERK pathways act synergistically to enhance antiangiogenic effects of EGCG through activation of FOXO transcription factor. J Mol Signal 3: 7, 2008.
32. Yu C, Dai Y, Dent P and Grant S: Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571. Cancer Biol Ther 1: 674-682, 2002.
33. Yang X, Galinsky I, DeAngelo DJ, Sternberg D and Stone RM: Apoptosis suppression by FLT3 activated via an internal tandem duplication mutation (ITD) requires both the MEK/ERK and PI3K/AKT signaling pathways [suppl 1]. Blood 100: 549a, 2003.
34. Martelii AM, Tazzari PL, Tabellini G, Bortul R, Billi AM, Manzoli L, Ruggeri A, Conte R and Cocco L: A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia 17: 1794-1805, 2003.
35. Benimetskaya L, Miller P, Benimetsky S, Maciaszek A, Guga P, Beaucage SL, Wilk A, Grajkowski A, Halperin AL and Stein CA: Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells. Mol Pharmacol 60: 1296-1307, 2001.
36. Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari A, Schober WD, Harris D, Leysath CE, Lopez-Berestein G, Huang Z and Andreeff M: Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood 99: 3461-3464, 2002.
37. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, Shokat KM and Weiss WA: A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9: 341-349, 2006.
38. Ikezoe T, Nishioka C, Bandobashi K, Yang Y, Kuwayama Y, Adachi Y, Takeuchi T, Koeffler HP and Taguchi H: Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leuk Res 31: 673-682, 2007.
39. Hanada M, Feng J and Hemmings BA: Structure, regulation and function of PKB/AKT - a major therapeutic target. Biochim Biophys Acta 1697: 3-16, 2004.
40. Torres J and Pulido R: The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. J Biol Chem 276: 993-998, 2001.
41. Meggio F and Pinna LA: One-thousand-and-one substrates of protein kinase CK2α FASEB J 17: 349-368, 2003.
42. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, Luger SM and Jordan CT: Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98: 2301-2307, 2006.
43. Shelton JG, Blalock WL, White ER, Steelman LS and McCubrey JA: Ability of the activated PI3K/Akt oncoproteins to synergize with MEK1 and induce cell cycle progression and abrogate the cytokine-dependence of hematopoietic cells. Cell Cycle 3: 503-512, 2004.
44. Killmann SA: Acute leukaemia: development, remission/relapse pattern, relationship between normal and leukaemic haemopoiesis, and the 'sleeper-to-feeder' stem cell hypothesis. Baillieres Clin Haematol 4: 577-598, 1991.